The usability of ALT measurements in the population of patients with MDS should be considered because most have not presented the exclusion criteria for using ALT as a biomarker for sarcopenia (e.g., advanced kidney failure, active or chronic hepatitis, and dependence on the regular usage of anti-PD medications). Here, GPT is linked to sarcopenia.